| 抗雄激素药物治疗去势抵抗型前列腺癌的机制研究进展 |
| |
| 引用本文： | 王前奔,吴大勇.抗雄激素药物治疗去势抵抗型前列腺癌的机制研究进展[J].中国肿瘤临床,2015,42(20):1002-1006. |
| |
| 作者姓名： | 王前奔 吴大勇 |
| |
| 作者单位： | 作者单位:美国俄亥俄州立大学分子病毒学、免疫学和医学遗传学系,美国俄亥俄州立大学综合癌症中心(美国俄亥俄州哥伦布市43210 ) |
| |
| 摘 要： | 去势抵抗型前列腺癌（castration-resistant prostate cancer ，CRPC）是指经内分泌治疗产生耐药并继续发展的致命性前列腺癌，雄激素受体（androgen receptor，AR）激活途径仍是这一阶段前列腺癌发展的驱动机制，因此抗雄激素治疗仍然是重要的治疗手段之一。虽然许多新型抗雄激素治疗药物在临床治疗中显示了显著的疗效，但同时耐药也频繁出现。本文就近年来几种主要抗雄激素治疗药物的作用及相应的耐药机制进行综述。
|
| 关 键 词： | 去势抵抗型前列腺癌? 雄激素受体 抗雄激素 分子机制 |
| 收稿时间： | 2015-09-16 |
Advances in understanding the mechanisms of anti-androgen therapeutic action and failure in castration-resistant prostate cancer |
| |
| Institution: | Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University College of Medicine, Columbus 43210, USA |
| |
| Abstract: | Castration-resistant prostate cancer (CRPC) is the lethal form of prostate cancer with developed resistance to androgen deprivation therapy. However, anti- androgen therapy remains an important treatment option because androgen receptor activation is a major driver of the advanced phase of CRPC. Drug resistance is frequently manifested despite the development of various novel anti-an-drogens with significant clinical efficacy. This review introduces several drugs prevalently used to treat CRPC. The mechanisms of ac-tion and pathways to resistance of these drugs are also discussed. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
| 点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
